Navigation Links
Cepheid Reports 2009 First Quarter Results
Date:4/23/2009

6 ------ ------ Total assets $190,643 $187,120 ======== ======== LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $15,081 $9,669 Accrued compensation 5,923 7,919 Accrued royalties 7,860 5,953 Accrued collaboration profit sharing 870 2,023 Accrued other liabilities 7,722 6,816 Current portion of deferred revenue 2,214 2,834 Bank borrowing 14,598 14,639 ------ ------ Total current liabilities 54,268 49,853 Long-term portion of deferred revenue 1,810 1,753 Other liabilities 4,820 3,549 ----- ----- Total liabilities 60,898 55,155 ------ ------ Shareholders' equity: Common stock 268,541 266,991 Additional paid-in capital 45,230 41,619 Accumulated other comprehensive income (loss) 19 (23) Accumulated deficit (184,045) (176,622) --------- --------- Total shareholders' equity 129,745 131,965 ------- ------- Total li
'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ALTO, Calif. (PRWEB) , ... July 02, 2015 , ... ... to improve an individual’s quality of sleep, launched its Indiegogo campaign on June 23. ... functionality: Luzi's voice command technology makes it effortless to use, while the integration of ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... IN (PRWEB) , ... July 01, 2015 , ... Apex ... 2015 BIO International Convention in Philadelphia, PA. , The presentation took place ... and outlined the plans for the development of APX3330 for the treatment of pancreatic ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... Global Challenges Require ... ... opportunity today to engage, innovate and deliver sustainable solutions to the growing global marketplace, said ... of the Delhi Sustainable Development Summit 2010 in India. , , , , ...
... , , SAO PAULO , ... has confirmed that ethanol made from sugarcane is a low ... greenhouse gas,(GHG) emissions. As part of today,s announcement finalizing regulations ... designated,sugarcane ethanol as an advanced biofuel that lowers GHG emissions ...
... Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in ... Johanna Bendell , Director, GI Oncology Research, Sarah Cannon ... /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (Nasdaq: AEZS ; ... specialized in oncology and endocrinology, today announced that its ...
Cached Biology Technology:Sustainability Is A Business Imperative 2EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 2EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 3EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 4Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 2Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 3Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 4Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 5Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 6
(Date:6/17/2015)... , and HILDEN, Germany , June 17, ... ; Frankfurt Prime Standard: QIA) today launched new Investigator ® ... forensic laboratories in the United States . ... simultaneously analyze multiple key genomic markers (short tandem repeats or ... Quality Sensor to evaluate the quality of DNA in each ...
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... that shifts the body's fuel consumption from glucose to fat ... team led by scientists at The University of Texas Medical ... Nature. , While their findings could provide new ... signal that emerged from the dark also presents a new ...
... newly identified human bocavirus was found in nearly 5 ... very young children. Researchers from the Centers for ... the International Conference on Emerging Infectious Diseases , "Our ... with pneumonia in Thailand, especially among young children," says ...
... Institute of Allergy and Infectious Diseases (NIAID), part of ... defect in the immune response of people with the ... of developing serious complications following smallpox vaccination. Led by ... Medical and Research Center in Denver, the researchers used ...
Cached Biology News:Darkness unveils vital metabolic fuel switch between sugar and fat 2Darkness unveils vital metabolic fuel switch between sugar and fat 3Bocavirus infection may be associated with pneumonia in Thailand, especially in children 2Defective immune system response to smallpox vaccine detailed in new study 2Defective immune system response to smallpox vaccine detailed in new study 3
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: